Antineoplastic Agents, Hormonal

Publication Title: 
Critical Reviews in Oncology/Hematology

Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. AI are often associated with significant joint and muscular symptoms; symptoms that are commonly referred to as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). AIMSS adversely impacts health-related quality of life of many patients, and reduces AI compliance.

Author(s): 
Roberts, Kate
Rickett, Kirsty
Greer, Ristan
Woodward, Natasha
Publication Title: 
Laboratory Investigation; a Journal of Technical Methods and Pathology

The protective effect of heme oxygenase-1 (HO-1) expression in cardiovascular disease has been previously demonstrated using transgenic animal models in which HO-1 is constitutively overexpressed in the heart. However, the temporal requirements for protection by HO-1 induction relative to injury have not been investigated, but are essential to employ HO-1 as a therapeutic strategy in human cardiovascular disease states.

Author(s): 
Hull, Travis D.
Bolisetty, Subhashini
DeAlmeida, Angela C.
Litovsky, Silvio H.
Prabhu, Sumanth D.
Agarwal, Anupam
George, James F.
Publication Title: 
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

PURPOSE: Hot flashes are a significant problem for many breast cancer survivors. Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life. A well-tolerated and effective mind-body treatment for hot flashes would be of great value. On the basis of previous case studies, this study was developed to evaluate the effect of a hypnosis intervention for hot flashes. PATIENTS AND METHODS: Sixty female breast cancer survivors with hot flashes were randomly assigned to receive hypnosis intervention (five weekly sessions) or no treatment.

Author(s): 
Elkins, Gary
Marcus, Joel
Stearns, Vered
Perfect, Michelle
Rajab, M. Hasan
Ruud, Christopher
Palamara, Lynne
Keith, Timothy
Publication Title: 
Carcinogenesis

The objective of this work was to determine the interactive effects between soy bioactive components and tamoxifen (TAM) on prevention of estrogen-dependent breast cancer (BRCA). We initially investigated the effects of soy isoflavone genistein and TAM on the growth and cell cycle progression of estrogen-dependent MCF-7 human BRCA cells, and on the expression of ERalpha, pS2 and EGFR genes in vitro. Genistein or TAM alone inhibited the growth of MCF-7 cells in part via G(1) phase arrest, but their combinations showed suggestive antagonistic effects.

Author(s): 
Mai, Zhiming
Blackburn, George L.
Zhou, Jin-Rong
Publication Title: 
Pancreas

OBJECTIVE: Octreotide is used to treat patients with neuroendocrine tumors. Previous reports show that octreotide long-acting repeatable (LAR) dose and patient body weight affect nadir plasma octreotide levels (approximately 1250, 2500, 5000, and 11,000 pg/mL for LAR doses of 10, 20, 30 and 60 mg/mo). However, plasma octreotide levels have decreased over time in patients receiving these doses of LAR. METHODS: From November 2004 until July 2007, trough plasma octreotide levels were determined in 86 patients on long-term octreotide LAR therapy at doses of 30, 60, and 120 mg/mo.

Author(s): 
Woltering, Eugene A.
Salvo, Vergilio A.
O'Dorisio, Thomas M.
Lyons, John
Li, Gang
Zhou, Ying
Seward, Jacky R.
Go, Vay Liang W.
Vinik, Arthur I.
Mamikunian, Paris
Mamikunian, Gregg
Publication Title: 
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

PURPOSE: Hot flashes are a significant problem for many breast cancer survivors. Hot flashes can cause discomfort, disrupted sleep, anxiety, and decreased quality of life. A well-tolerated and effective mind-body treatment for hot flashes would be of great value. On the basis of previous case studies, this study was developed to evaluate the effect of a hypnosis intervention for hot flashes. PATIENTS AND METHODS: Sixty female breast cancer survivors with hot flashes were randomly assigned to receive hypnosis intervention (five weekly sessions) or no treatment.

Author(s): 
Elkins, Gary
Marcus, Joel
Stearns, Vered
Perfect, Michelle
Rajab, M. Hasan
Ruud, Christopher
Palamara, Lynne
Keith, Timothy
Publication Title: 
Cancer

BACKGROUND: Arthralgia is common in postmenopausal breast cancer survivors (BCS) who are receiving aromatase inhibitors (AIs). The objective of this study was to evaluate the perceived onset, characteristics, and risk factors for AI-related arthralgia (AIA). METHODS: In a cross-sectional survey of postmenopausal BCS who were receiving adjuvant AI therapy at a university-based oncology clinic, patient-reported attribution of AIs as a cause of joint pain was used as the primary outcome. Multivariate logistic regression analyses were performed to evaluate risk factors.

Author(s): 
Mao, Jun J.
Stricker, Carrie
Bruner, Deborah
Xie, Sharon
Bowman, Marjorie A.
Farrar, John T.
Greene, Brandon T.
DeMichele, Angela
Publication Title: 
Pancreas

OBJECTIVES: Octreotide long acting repeatable (LAR) is commonly used to control the symptoms of patients with functional neuroendocrine tumors. Unfortunately, most patients escape control over time and require higher LAR doses or more frequent rescue therapy to remain asymptomatic. Previous work has shown that body weight and monthly LAR dose will significantly affect circulating plasma octreotide levels in patients undergoing therapy.

Author(s): 
Joseph, Saju
Li, Gang
Lindholm, Erika
Zhou, Ying
Go, Vay Liang W.
Vinik, Aaron I.
O'Dorisio, Thomas M.
Mamikunian, Gregg
Woltering, Eugene A.
Publication Title: 
Breast cancer research: BCR

INTRODUCTION: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors develop resistance. 14-3-3 ζ/YWHAZ, a member of the 14-3-3 family of conserved proteins, is over-expressed in several types of cancer, and our previous work showed that high expression of 14-3-3ζ in ER-positive breast cancers was associated with a poor clinical outcome for women on tamoxifen. Therefore, we now probe the role of 14-3-3ζ in endocrine resistance, and we examine the functional dimensions and molecular basis that underlie 14-3-3ζ activities.

Author(s): 
Bergamaschi, Anna
Christensen, Barbara L.
Katzenellenbogen, Benita S.
Publication Title: 
Carcinogenesis

The present study examined the effect of dietary genistein, a soy isoflavone, on breast cancer patients who take tamoxifen, an antiestrogen treatment, using a preclinical model. The interaction of various doses of genistein with tamoxifen on the growth of estrogen receptor-positive breast cancer MCF-7 cells was investigated by subcutaneously injecting MCF-7 cells into the flank of ovariectomized athymic mice.

Author(s): 
Du, Mengyuan
Yang, Xujuan
Hartman, James A.
Cooke, Paul S.
Doerge, Daniel R.
Ju, Young H.
Helferich, William G.

Pages

Subscribe to RSS - Antineoplastic Agents, Hormonal